Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immunoprecise Antibodies Ltd is a biotechnology business based in the US. Immunoprecise Antibodies shares (IPA) are listed on the NASDAQ and all prices are listed in US Dollars. Immunoprecise Antibodies employs 73 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $3.95 |
|---|---|
| 52-week range | $3.51 - $16.47 |
| 50-day moving average | $4.91 |
| 200-day moving average | $5.44 |
| Wall St. target price | $12.05 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.95 from 2022-07-05
| 1 week (2022-06-30) | 3.95% |
|---|---|
| 1 month (2022-06-06) | -27.52% |
| 3 months (2022-04-07) | -28.44% |
| 6 months (2022-01-06) | -34.06% |
| 1 year (2021-07-07) | -33.39% |
|---|---|
| 2 years (2020-07-07) | 329.35% |
| 3 years (2019-07-05) | 642.48% |
| 5 years (2017-07-05) | 353.29% |
| Revenue TTM | $19 million |
|---|---|
| Gross profit TTM | $11.4 million |
| Return on assets TTM | -18.66% |
| Return on equity TTM | -42.77% |
| Profit margin | -89.98% |
| Book value | $2.45 |
| Market capitalisation | $90.4 million |
TTM: trailing 12 months
We're not expecting Immunoprecise Antibodies to pay a dividend over the next 12 months.
You may also wish to consider:
Immunoprecise Antibodies's shares were split on a 1:5 basis on 22 November 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunoprecise Antibodies shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Immunoprecise Antibodies shares which in turn could have impacted Immunoprecise Antibodies's share price.
Over the last 12 months, Immunoprecise Antibodies's shares have ranged in value from as little as $3.51 up to $16.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunoprecise Antibodies's is -0.2276. This would suggest that Immunoprecise Antibodies's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Immunoprecise Antibodies has bucked the trend.
To put Immunoprecise Antibodies's beta into context you can compare it against those of similar companies.
ImmunoPrecise Antibodies Ltd. , together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S. A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.